Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Subscribe To Our Newsletter & Stay Updated